gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
buy valuat make good entri
data
data cohort sunrise-pd phase ii trial
lentiviral-bas gt axo-lenti-pd parkinson diseas pd
discontinu collabor benitec biopharma
unrat expect dataset
axov addit present compani updat yesterday
axo-lenti-pd data larg consist prior
month data littl mitig chief concern month
post-treat patient treat cohort improv
baselin updr score point averag
point vs point averag improv
baselin updr ii score point vs point
updr iv score point vs point
patient show decreas levodopa equival daili
dose ledd averag vs
vs declin baselin experienc averag
vs improv function disabl measur
rush dyskinesia rate scale qualiti life also measur
parkinson diseas show averag
improv baselin month month
consid overal result small sampl patient roughli
consist result seen month though axov show
improv seen dataset prosavin dataset
potenti axo-lenti-pd set new label standard reiter
caution earli pd data due histori placebo effect
pd trial due potenti efficaci hawthorn effect
patient feign wors symptom baselin inclus studi
discontinu licens collabor benitec
neg show abil axov fail fast without
previous includ axo-aav-opmd oculopharyng muscular
dystrophi opmd discoveri program includ
amyotroph later sclerosi al frontotempor dementia ftd
press releas benitec explain develop
axo-aav-opmd would requir addit preclin work
would delay initi clinic studi beyond timelin
initi outlin cost failur case includ
million up-front payment disclos juli announc
us interest catalyst
gangliosidosi readout expect
pleas refer import disclosur inform regul analyst certif found page report
gangliosidos see higher potenti asset transform axov valuat given fatal natur
diseas life expect year therapi approv disease-modifi treatment
low amount enzym product gt may abl transform clinic outcom due lower competit
intens indic gt indic success axov could prove transform
recal may axov announc dose patient phase trial compani
yesterday affirm preliminari data trial expect axov march earlier report
data patient phase trial see march research expect report data
addit patient point roivant pipelin day axov note gangliosidosi
tay-sach diseas restor -hexosaminidas hexa enzym defici even normal
level could translat clinic meaning result patient data patient though definit
least encourag regard await addit data see progress along dimens
axo-lenti-pd provid initi data cohort phase ii trial pd
axo-lenti-pd decis move part random sham control phase ii pd trial run dose
escal cohort part
provid initi data phase trial gangliosidosi
provid addit data patient optim rout deliveri phase trial
select axov relat research
march axgt upgrad buy unchang valuat rel opportun
februari viral news genet medicin review expect
june axon neutral enter gt via global right parkinson
march axon close vtvt axon pair trade alpha gener
januari axon upgrad sell neutral recent under-perform
januari axon sell thesi intepirdin confirm
septemb axon sell thesi confirmedintepirdin fail piii mindset trial
septemb axon reiter sell reason like downsid share
decemb initi sell unlik show proof concept
june initi sell highli irrat market price
price target base valu compani roughli cash shall move patient-bas
model key franchis consist approach sector disclosur axov key program
risk achiev target price
clinic risk axov also develop vector gene therapi condit parkinson diseas
gangliosidosi gangliosidosi tay-sach sandhoff diseas safeti signal lack efficaci
preclin clinic studi could neg impact axov sentiment and/or valuat
regulatori even result clinic program axo-lenti-pd achiev target
endpoint product obtain regulatori approv price target would expos downward revis
anoth concern approv may narrow indic expect subject costli post-approv
commerci potenti axov target indic may larg consensu project possibl
due competit price axov gene therapi might prove high market bear addit axov
build sale market medic affair infrastructur us possibl global region
intellectu properti although axov certain highly-robust protect key franchis axov part reli
ip organ due novelti gene therapi product unclear extent product
patent protect beyond initi regulatori exclusivity/or orphan drug design
page
manufactur note higher frequenc manufactur setback difficult-to-mak product time
stock price volatil share price volatil common development compani biotechnolog sector
axov gene therapi ltd clinical-stag gene therapi compani focus develop pipelin innov
product candid debilit neurolog neuromuscular diseas compani pipelin gene therapi
candid includ clinic program gangliosidosi gangliosidosi includ tay-sach diseas
sandhoff diseas parkinson diseas
page
rate price target histori axov gene therapi ltd
creat bluematrix
rate price target histori inc
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori inc
creat bluematrix
rate price target histori uniqur qure
rate price target histori regenxbio inc
creat bluematrix
creat bluematrix
page
rate price target histori inc
rate price target histori appli genet corpor agtc
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori plc
rate price target histori nightstar therapeut nite
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori gensight biolog sight fp
rate price target histori toolgen inc
creat bluematrix
creat bluematrix
rate price target histori arbutu biopharma corpor abu
creat bluematrix
page
rate price target histori inc
rate price target histori arcturu therapeut ltd arct
creat bluematrix
rate price target histori arrowhead inc
creat bluematrix
creat bluematrix
page
rate price target histori audent inc bold
creat bluematrix
rate price target histori inc
creat bluematrix
rate price target histori iovanc inc
creat bluematrix
page
rate price target histori inc
rate price target histori medicin compani mdco
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori novarti ag nv
rate price target histori proqr nv prqr
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori
rate price target histori tocagen inc
creat bluematrix
rate price target histori vascular biogen ltd vblt
creat bluematrix
creat bluematrix
page
rate price target histori crispr ag crsp
creat bluematrix
distribut ratings/ib servic
analyst certif analyst respons cover secur report certifi view
express research report accur reflect person view compani secur analyst
respons cover secur report certifi part compens directli
indirectli relat specif recommend view contain research report
